Tirzepatide and Pregnancy: How Soon Can You Try to Conceive After Stopping Zepbound or Mounjaro?

You can safely begin trying to conceive about one full menstrual cycle (4–5 weeks) after your last dose of tirzepatide. This interval, which covers at least five drug half-lives, allows Zepbound or Mounjaro to fall to clinically insignificant levels, lowering the theoretical risk of fetal growth restriction seen in animal studies. If pregnancy occurs sooner, stop the injection immediately and contact your OB-GYN or a telehealth physician to adjust treatment.

• Tirzepatide’s elimination half-life is about 5 days, so more than 95 % of the drug leaves the body after 25–30 days. (accessdata.fda.gov)
• FDA labels for Zepbound and Mounjaro state: “When pregnancy is recognized, discontinue tirzepatide” because animal studies showed dose-related fetal growth reductions. (accessdata.fda.gov)
• Clinical guidelines in the United States and United Kingdom recommend stopping tirzepatide at least 1 month before a planned pregnancy. (diabetesjournals.org)
• No human birth-defect signal has emerged, but data are still limited; a manufacturer-run pregnancy registry is now enrolling. (accessdata.fda.gov)
• Breast-milk studies found either undetectable or <0.02 % of the maternal dose, yet most clinicians prefer alternative agents while nursing. (accessdata.fda.gov)

Tirzepatide is a dual GIP/GLP-1 injectable that lowers blood sugar and weight but carries an FDA pregnancy warning

Definition: Tirzepatide is a once-weekly peptide that stimulates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors to slow gastric emptying, curb appetite, and improve glycemic control. The brands Mounjaro (type 2 diabetes) and Zepbound (obesity) earned FDA approvals in 2022 and 2023, respectively. (accessdata.fda.gov)

Pregnancy category: Both labels list “May cause fetal harm. Discontinue when pregnancy is recognized.” Animal studies revealed reduced fetal weight and skeletal malformations at exposures as low as 0.5-fold the human dose. (accessdata.fda.gov)

Because these adverse findings occurred in the setting of significant maternal weight loss, regulators require post-marketing pregnancy registries and advise pre-pregnancy discontinuation.

Weight loss and potential fetal harm are the two main reasons tirzepatide is halted during pregnancy

Stopping tirzepatide as soon as pregnancy is confirmed protects both parent and baby.

Mandatory weight gain: Healthy gestation needs gradual maternal weight gain; active weight-loss therapies can impair placental growth and nutrient delivery. (accessdata.fda.gov)

Animal toxicity signal: Rat and rabbit data showed fetal growth restriction, ossification delays, and higher rates of malformations at clinically relevant exposures (0.5 mg/kg in rats; 0.1 mg/kg in rabbits). (accessdata.fda.gov)

Unknown human risk: No large human cohort exists yet, so regulators take a precautionary approach.

Tirzepatide’s half-life is 5 days, so it is cleared in about 25–30 days

Tirzepatide reaches peak plasma levels 8–12 hours after injection and has a terminal half-life of roughly 5 days. Five half-lives (25 days) remove >95 % of the drug. (accessdata.fda.gov)

How long to wait before IVF, egg freezing, or natural conception

Guidelines from the American Diabetes Association and the U.K. National Institute for Health and Care Excellence suggest a one-month wash-out before pregnancy attempts. (diabetesjournals.org) Below is how that translates in practice:

Egg freezing note: The trigger injection and retrieval can proceed as soon as weight stabilizes and at least 14 days have passed to avoid pharmacodynamic overlap.

What if you become pregnant while still taking tirzepatide?

Immediate steps: Skip the next weekly shot and contact your OB or a telehealth clinician. No evidence suggests that a single early-pregnancy dose is teratogenic, but monitoring is prudent.

Switch to pregnancy-safe treatments: For diabetes, insulin or metformin have human safety data. For obesity without diabetes, lifestyle therapy is first-line.

Is tirzepatide safe during breastfeeding?

In a single-dose study of 11 lactating women given 5 mg tirzepatide, drug levels in 164 of 171 milk samples were below the 4 ng/mL detection limit; the highest measured infant exposure was <0.02 % of the maternal dose. (accessdata.fda.gov)

Despite low transfer, clinicians usually avoid tirzepatide while nursing because:

• Limited long-term data: No infant growth studies exist.
• Postpartum calorie needs: Restrictive weight-loss therapy can reduce milk supply.
• Safer alternatives: Insulin (for diabetes) or dietary coaching can bridge the gap.

You may restart Zepbound or Mounjaro after fully weaning and once your provider confirms it is appropriate.

Current data do not show tirzepatide harming sperm or testosterone

Fertility studies in male rats found no adverse effects on sperm morphology or conception rates, even at exposures twice the human dose. (accessdata.fda.gov) Human studies are lacking, but no increase in infertility has been reported in clinical trials.

Healthy weight and optimized metabolic markers after GLP-1 therapy may actually improve male reproductive parameters.